- Home
- Publications
- Publication Search
- Publication Details
Title
Aldo-Keto Reductase (AKR) 1C3 inhibitors: a patent review
Authors
Keywords
-
Journal
EXPERT OPINION ON THERAPEUTIC PATENTS
Volume 27, Issue 12, Pages 1329-1340
Publisher
Informa UK Limited
Online
2017-09-12
DOI
10.1080/13543776.2017.1379503
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Discovery of (R)-2-(6-Methoxynaphthalen-2-yl)butanoic Acid as a Potent and Selective Aldo-keto Reductase 1C3 Inhibitor
- (2016) Adegoke Adeniji et al. JOURNAL OF MEDICINAL CHEMISTRY
- Inhibition of AKR1C3 Activation Overcomes Resistance to Abiraterone in Advanced Prostate Cancer
- (2016) Chengfei Liu et al. MOLECULAR CANCER THERAPEUTICS
- Intracrine Androgens and AKR1C3 Activation Confer Resistance to Enzalutamide in Prostate Cancer
- (2015) C. Liu et al. CANCER RESEARCH
- The DHEA-sulfate depot following P450c17 inhibition supports the case for AKR1C3 inhibition in high risk localized and advanced castration resistant prostate cancer
- (2015) Daniel Tamae et al. CHEMICO-BIOLOGICAL INTERACTIONS
- Screening baccharin analogs as selective inhibitors against type 5 17β-hydroxysteroid dehydrogenase (AKR1C3)
- (2015) Tianzhu Zang et al. CHEMICO-BIOLOGICAL INTERACTIONS
- Androgen receptor splice variants activating the full-length receptor in mediating resistance to androgen-directed therapy
- (2015) Bo Cao et al. Oncotarget
- Rapid Induction of Androgen Receptor Splice Variants by Androgen Deprivation in Prostate Cancer
- (2014) Z. Yu et al. CLINICAL CANCER RESEARCH
- Canonical Androstenedione Reduction Is the Predominant Source of Signaling Androgens in Hormone-Refractory Prostate Cancer
- (2014) M. Fankhauser et al. CLINICAL CANCER RESEARCH
- In vitro and in vivo characterisation of ASP9521: a novel, selective, orally bioavailable inhibitor of 17β-hydroxysteroid dehydrogenase type 5 (17βHSD5; AKR1C3)
- (2014) Aya Kikuchi et al. INVESTIGATIONAL NEW DRUGS
- Safety, tolerability and anti-tumour activity of the androgen biosynthesis inhibitor ASP9521 in patients with metastatic castration-resistant prostate cancer: multi-centre phase I/II study
- (2014) Yohann Loriot et al. INVESTIGATIONAL NEW DRUGS
- Intense Androgen-Deprivation Therapy With Abiraterone Acetate Plus Leuprolide Acetate in Patients With Localized High-Risk Prostate Cancer: Results of a Randomized Phase II Neoadjuvant Study
- (2014) Mary-Ellen Taplin et al. JOURNAL OF CLINICAL ONCOLOGY
- Isoquinoline alkaloids as a novel type of AKR1C3 inhibitors
- (2014) Lucie Skarydova et al. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY
- The Link Between Androgen Receptor Splice Variants and Castration-Resistant Prostate Cancer
- (2014) Cynthia C. T. Sprenger et al. Hormones & Cancer
- A Gain-of-Function Mutation in DHT Synthesis in Castration-Resistant Prostate Cancer
- (2013) Kai-Hsiung Chang et al. CELL
- Steroidogenic Enzyme AKR1C3 Is a Novel Androgen Receptor-Selective Coactivator that Promotes Prostate Cancer Growth
- (2013) M. Yepuru et al. CLINICAL CANCER RESEARCH
- Synthesis and structure–activity relationships for 1-(4-(piperidin-1-ylsulfonyl)phenyl)pyrrolidin-2-ones as novel non-carboxylate inhibitors of the aldo-keto reductase enzyme AKR1C3
- (2013) Daniel M. Heinrich et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- 2,3-Diarylpropenoic acids as selective non-steroidal inhibitors of type-5 17β-hydroxysteroid dehydrogenase (AKR1C3)
- (2013) Martin Gazvoda et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Development of Potent and Selective Indomethacin Analogues for the Inhibition of AKR1C3 (Type 5 17β-Hydroxysteroid Dehydrogenase/Prostaglandin F Synthase) in Castrate-Resistant Prostate Cancer
- (2013) Andy J. Liedtke et al. JOURNAL OF MEDICINAL CHEMISTRY
- Unknown
- (2013) Agus Hamid et al. MOLECULAR MEDICINE
- N-Benzoyl anthranilic acid derivatives as selective inhibitors of aldo–keto reductase AKR1C3
- (2012) Maša Sinreih et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Crystal structures of AKR1C3 containing an N-(aryl)amino-benzoate inhibitor and a bifunctional AKR1C3 inhibitor and androgen receptor antagonist. Therapeutic leads for castrate resistant prostate cancer
- (2012) Mo Chen et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment
- (2012) N. J. Clegg et al. CANCER RESEARCH
- Distinct Patterns of Dysregulated Expression of Enzymes Involved in Androgen Synthesis and Metabolism in Metastatic Prostate Cancer Tumors
- (2012) N. Mitsiades et al. CANCER RESEARCH
- Development of Potent and Selective Inhibitors of Aldo–Keto Reductase 1C3 (Type 5 17β-Hydroxysteroid Dehydrogenase) Based on N-Phenyl-Aminobenzoates and Their Structure–Activity Relationships
- (2012) Adegoke O. Adeniji et al. JOURNAL OF MEDICINAL CHEMISTRY
- Selective Inhibition of Human Type-5 17β-Hydroxysteroid Dehydrogenase (AKR1C3) by Baccharin, a Component of Brazilian Propolis
- (2012) Satoshi Endo et al. JOURNAL OF NATURAL PRODUCTS
- Overexpression of aldo-keto reductase 1C3 (AKR1C3) in LNCaP cells diverts androgen metabolism towards testosterone resulting in resistance to the 5α-reductase inhibitor finasteride
- (2012) Michael C. Byrns et al. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY
- Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
- (2012) Howard I. Scher et al. NEW ENGLAND JOURNAL OF MEDICINE
- Straightforward protocol for the efficient synthesis of varied N1-acylated (aza)indole 2-/3-alkanoic acids and esters: optimization and scale-up
- (2012) Andy J. Liedtke et al. TETRAHEDRON
- Discovery of substituted 3-(phenylamino)benzoic acids as potent and selective inhibitors of type 5 17β-hydroxysteroid dehydrogenase (AKR1C3)
- (2011) Adegoke O. Adeniji et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Activation of the Androgen Receptor by Intratumoral Bioconversion of Androstanediol to Dihydrotestosterone in Prostate Cancer
- (2011) James L. Mohler et al. CANCER RESEARCH
- Potential Prostate Cancer Drug Target: Bioactivation of Androstanediol by Conversion to Dihydrotestosterone: Figure 1.
- (2011) James L. Mohler et al. CLINICAL CANCER RESEARCH
- Clinical and Biochemical Consequences of CYP17A1 Inhibition with Abiraterone Given with and without Exogenous Glucocorticoids in Castrate Men with Advanced Prostate Cancer
- (2011) Gerhardt Attard et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Unknown
- (2011) Minja Pfeiffer et al. MOLECULAR MEDICINE
- Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer
- (2011) K.-H. Chang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Evidence of Limited Contributions for Intratumoral Steroidogenesis in Prostate Cancer
- (2010) J. Hofland et al. CANCER RESEARCH
- Inhibitors of type 5 17β-hydroxysteroid dehydrogenase (AKR1C3): Overview and structural insights
- (2010) Michael C. Byrns et al. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY
- Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study
- (2010) Howard I Scher et al. LANCET
- Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer
- (2010) Karen E. Knudsen et al. TRENDS IN ENDOCRINOLOGY AND METABOLISM
- Starving the Addiction: New Opportunities for Durable Suppression of AR Signaling in Prostate Cancer
- (2009) K. E. Knudsen et al. CLINICAL CANCER RESEARCH
- Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate Cancer
- (2009) Gerhardt Attard et al. JOURNAL OF CLINICAL ONCOLOGY
- Aldo-keto reductase 1C3 expression in MCF-7 cells reveals roles in steroid hormone and prostaglandin metabolism that may explain its over-expression in breast cancer
- (2009) Michael C. Byrns et al. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY
- Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer
- (2009) C. Tran et al. SCIENCE
- Expression of steroidogenic enzymes and sex-steroid receptors in human prostate
- (2008) Georges Pelletier BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM
- AKR1C3 as a potential target for the inhibitory effect of dietary flavonoids
- (2008) Lucie Škarydová et al. CHEMICO-BIOLOGICAL INTERACTIONS
- Intratumoral concentration of sex steroids and expression of sex steroid-producing enzymes in ductal carcinoma in situ of human breast
- (2008) R. Shibuya et al. ENDOCRINE-RELATED CANCER
- Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven
- (2008) Gerhardt Attard et al. JOURNAL OF CLINICAL ONCOLOGY
- An indomethacin analogue, N-(4-chlorobenzoyl)-melatonin, is a selective inhibitor of aldo-keto reductase 1C3 (type 2 3α-HSD, type 5 17β-HSD, and prostaglandin F synthase), a potential target for the treatment of hormone dependent and hormone independent malignancies
- (2007) Michael C. Byrns et al. BIOCHEMICAL PHARMACOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now